Speaker
Description
Astatine-211 (At-211) is a highly promising radionuclide for Targeted Alpha Therapy, particularly for the treatment of metastatic cancers. However, its clinical adoption remains limited by production challenges. At-211 is typically produced by irradiating bismuth targets with 28-30 MeV alpha particles. Conventional cyclotrons are commonly used for this purpose, although their beam currents rarely exceed 0.1 mA, thereby significantly limiting achievable production yields. Linear accelerators (LINACs) offer an attractive alternative due to their potential for substantially higher beam currents, in the mA range. The Tera-Care Foundation is developing a dedicated high-power target system designed to operate under kW-level power deposition and a pulsed-beam structure. Initial analysis focus on estimating thermal loads, energy deposition profiles, and resulting temperature distributions to determine safe operating limits and prevent material degradation. This work establishes the foundational design framework required to enable reliable, high-power production of At-211 using LINAC technology.
| Paper status | Resubmitted proceeding files received and assigned to an editor. Accepted by Submitter. |
|---|